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Purpose. We reviewed our 20 years of experience and the current literature regarding the long-term outcome of endoscopic
treatment of vesicoureteric reﬂux (VUR) using the diﬀerent tissue bulking substances with a special emphasis on the long-term
eﬃcacy. Material and Methods. Our own experience and the current literature on the long-term results after endoscopic treatment
using various bulking agents were reviewed. Results. Short-term data following endoscopic treatment of VUR is similar to the
various substances and comparable in the majority of the series to the success rate following open surgery. Recently, a relatively
high recurrence rate was noticed especially with the use of dextranomer hyaluronic acid (Dx/HA) as a tissue augmenting material
which raises the need for further search for alternative substances. Conclusions. Unfortunately, there is a signiﬁcant shortage of
evidence-based literature on the long-term followup after endoscopic correction of reﬂux with various substances. No doubt,
there is a high recurrence rate during long-term followup after Dx/HA injection, and there is probably lack of proper evaluation
regarding the long-term eﬃcacyofotherbulkingmaterials.Thesefactsdemandlong-termcloseobservationandlong-termstudies
beyond the routine protocols following endoscopic treatment of VUR and the correct parental counseling upon the endoscopic
correction.
1.Introduction
The introduction of STING two decades ago started the
change in the treatment of VUR. Since the approval by the
Food and Drug Administration (FDA) of Dx/HA copoly-
mer (Deﬂux, Q-Med Scandinavia, Uppsala, Sweden) over
the last 7 years, the endoscopic management of VUR has
emerged as a ﬁrst line treatment in all grades of reﬂux in
most of the world [1–5]. The concept of the endoscopic
correction of VUR oﬀers a minimally invasive treatment
in the management of UTI or renal parenchymal damage
associated with reﬂux. The advantages of this procedure
are numerous: easy to perform, short, minimally invasive,
low complications rate, and short hospital stay. The overall
success rates which were reported by the diﬀerent groups
ranged between 68–92%, depending mainly on the VUR
grade [1–3, 6, 7]. The complications rate following this
procedure is infrequent and relates mainly to the obstruction
of ureterovesical junction (UVJ) and the development a new
contralateral reﬂux (NCVUR) following treatment of uni-
lateral VUR [5]. A recent meta-analysis of injection therapy
consideringoutcomesfromDx/HA,polytetraﬂuoroethylene,
collagen, polydimethylsiloxane, and chondrocytes suggested
fewer subsequent UTIs than previously noted with open
surgery or antibiotic prophylaxis, with an overall incidence
of 6% (range from 2.74% to 14.15%) and febrile infection
observed in only 0.75% of patients [8]. Furthermore, the
recently published American Urology Association (AUA)
guideline regarding VUR treatment clearly stated that febrile
UTI is strongly associated with renal parenchymal damage2 Advances in Urology
and that successful surgical correction leads to thesigniﬁcant
decrease of the pyelonephritis and therefore may avoid renal
scarring [9]. Since endoscopic treatment of UTI has enjoyed
a high rate of the success in the short-term followup, it
is extremely important to address the issue of the long-
term eﬃcacy and the subsequent UTI, pyelonephritis, and
renal scarring incidence following endoscopic correction of
UTI. In this paper, we have summarized the worldwide
experience with the long-term eﬃcacy of the diﬀerent
bulking agents utilized for endoscopic correction of VUR
with special emphasis on the UTI incidence and the long-
term eﬃcacy of Dx/HA copolymer as an ultimate tissue
augmenting substance used for the endoscopic injection in
the majority of the pediatric urology centers around the
world. In addition, we have reviewed a limited experience
with a new biodegradable bulking agent.
2.AReviewofthe VariousAvailable
Bulking Agents
2.1. Polytetraﬂuoroethylene (PTFE). PTFE belongs to the
group of the most widely used biomaterials in medicine.
Medical applications of the PTFE include vascular grafts,
heart valves, and tissue replacement patches. PTFE was one
of the ﬁrst widely used tissues augmenting substance for
endoscopic correction of reﬂux [4]. Since the published
experience with PTFE is over than 20 years of followup, it is
interesting to observe and to compare the incidence of UTI
and the long-term durability of PTFE with currently used
biomaterials for injection therapy.
The longest reported followup of children with primary
VUR treated with PTFE injection was published by Chertin
et al. [3]. The authors reported about 258 children with
primaryVUR,withamedianageof6yearscomprisingatotal
of 393 reﬂuxing ureters. Ninety-six percent of the injected
ureters had Grade III to V reﬂux. Eighty-eight percent of
patients had a routine voiding cystourethrogram (VCUG)
between 11 up to 17 years after the successful injection,
showing a high success rate of 95% therefore eliminating
the possibility of the silent VUR recurrence. Out of those 19
(5%) ureters, only 6 recurred showing a high-grade reﬂux.
The most striking fact in this study is that none of
the studied patients developed febrile UTI during and only
3.6% of children had afebrile UTI during followup. Similar
ﬁndings in terms of the VUR recurrence and incidence of
the febrile UTI were demonstrated by another study with a
followup of 10 years after PTFE injection [4].
Although the majority of the pediatric urologists have
acknowledged the eﬃcacy of endoscopic correction of low-
grade VUR, some still question the durability of the endo-
scopic correction in high-grade VUR [21]. The convincing
data regarding the long-term followup over 17 years with
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published previously [22]. In this study, 717 reﬂuxing units
were analyzed following PTFEE injection, reﬂux recurred
only in nine units (1.2%) further showing that, with the
correct choice of the implant for endoscopic correction, this
procedure is durable even in high-grade VUR.
Despite of the convincing data regarding the long-term
eﬃcacy of endoscopic correction of VUR utilizing PTFE,
the concerning information regarding the possibility of the
PTFE particle migration eliminated the use of PTFE for the
correction of VUR. For these reasons, alternative substances
have been developed (Table 1).
2.2. Glutaraldehyde Cross-Linked Bovine Collagen. Glu-
taraldehyde cross-linked bovine collagen has emerged as a
ﬁrst alternative to PTFE [11, 12]. Since the collagen was used
very intensively in the medical industry for the manufactur-
ing of cardiac valves and hemostatic agents, causing minimal
tissue reaction when locally injected, initially it appeared
as a promising substance for the VUR correction in the
short term. However, long-term studies clearly showed that
the initial success rate with the use of collagen dramatically
decreased during long-term followup. Reunane reported his
experience with collagen injection in 197 reﬂuxing ureters in
148children[12].Allchildrenunderwentdirectradionuclide
c y s t o g r a p h ya t1m o n t h ,6m o n t h s ,2y e a r s ,a n d4y e a r s
following endoscopic correction. The results for the low-
grade VUR were better than previously reported about this
s u b s t a n c ed e m o n s t r a t i n g9 3 . 9 %c u r e dr a t ea f t e ro n em o n t h
following injection; however, after 4 years only 81.8% cure
rate was documented. Patients with high-grade VUR and
complex cases did signiﬁcantly worse with 44.4% success
rates after 1 month and a very low cure rate at 4 years of only
21.4%.
These disappointing results further demonstrated by
Haferkamp et al. reporting prospectively about 36 patients
treated with single-collagen injection [11]. While they have
achieved 80% success at 3 months after injection, only 9%
of the previously cured ureters were still free of reﬂux at 37
months following injections.
Disappointing results ceased the use of Glutaraldehyde
cross-linked bovine collagen for the correction of VUR.
2.3. Polydimethylsiloxane (Macroplastique). Polydimethylsi-
loxane is a solid, elastomeric silicone, soft tissue bulking
agent that has been incorporated into a patented device
called Macroplastique (Uroplasty Inc., Geleen, The Nether-
lands) [13, 23–25]. In spite of the fact that the majority
of the particles of this agent are greater than 100µmi n
diameter, the presence of the particles with the size of 80µm
and less may still raise the fear from distant migration.
The short-term results with the use of Macroplastique as
a tissue augmenting substance were similar to the other
bulking agents [4]. However, there is a signiﬁcant shortage
of prospective long-term studies, which may prove the
eﬃcacy of silicon in the treatment of VUR. Van Capelle
et al. published a retrospective review on 195 patients
who underwent endoscopic correction of VUR utilizing
Macroplastique as a tissue augmenting substance in two
institutions [24]. The study period lasted over 10 years.
Overall success rate was 84% and 77%, respectively, in two
departments. One of the major drawbacks of this study, as
well as others dealing with long-term eﬃcacy of the bulking
agents,isthatthepatientswere discharged fromthefollowupAdvances in Urology 3
Table 1: Long-term results of endoscopic treatment of VUR.
Author Bulking agent Follow-up time (years) Short-term success rate (%) Long-term success rate (%)
Chertin et al. [10] PTFE 17 98.2 95
Chertin et al. [10] PTFE 10 100 91
Haferkamp et al. [11] Collagen 3 95 9
Reunane et al. [12] Collagen 4 93.9 81.8
D o d a te ta l .[ 13] Macroplastique 7 93.3 79.4
Caldamone et al. [14] Autologous Chondrocytes 3 83 70
Mevorach et al.[15]C o a p e t i t e 2 7 2 7 2
after one year if they were free of symptoms. The recent
review ofthe literature regarding long-term results of the use
ofMacroplastiqueinchildrenwith VURhas shownthat after
9 years of follow up the success rate is similar to the short-
term observation [26]. However, again, no precise criteria
regarding the followup details such as the percentage of the
patients who underwent obligatory VCUG and monitoring
of the UTI were clearly stated.
In summary, there is a lack of evidence-based data in
order to give a solid report about the long-term eﬃcacy of
this substance for the correction of VUR.
2.4. Autologous Chondrocytes. Autologous chondrocytes
were proposed by Atala and coworkers for the endoscopic
treatment of VUR following successful animal experiments
[14].However,theneedfortwoproceduresunderanesthesia,
the ﬁrst to harvest the cartilage cells for the preparation of
the injection solution and the second for the endoscopic
implantation, reduced the popularity of this substance.
Moreover, a signiﬁcant high-recurrence rate after one year
raised a serious question regarding the reliability of this
tissue augmenting substance in the pediatric population.
For the above-mentioned reasons, this substance was
abandoned.
2.5. Calcium Hydroxyapatite (Coaptite). Calcium hydrox-
yapatite has been used as a biocompatible implant for
orthopedic and dental procedures in humans for more than
25 years. In 1998, an FDA approved to study the use of
Coaptite, for the urinary tract. Coaptite was used in women
as a bulking agent for the treatment of female stress urinary
incontinence. The initial results, safety and durability of
the material for 3 years, prompted the FDA decision to
approve a pilot investigation for the use of Coaptite in
the treatment of VUR in children. In 2001, given initially
favorable results of the pilot VUR study (70% cure in 10
patients/10 ureters at 3 months), a prospective multicenter
trial of synthetic calcium hydroxyapatite, as a subureteral
bulking agent, in children with traditional indications for
surgicaltreatment ofVURwasperformed at10UnitedStates
centers [15]. At 1 and 2 years, 24 out of 74 patients (32%)
were cured. Ureteral cure rates were 46% and 40% at 1 and
2 years, respectively. With 35 patients treated and 85% com-
pliance with the required 2-year VCUG, the primary center
achieved 2-year cure rates of 66% of patients and 72% of
ureters.
Small study cohort and relatively short-term followup
avoids the ability to give a true evidence-base-judgment
about this substance as a bulking injectable agent for the
treatment of VUR in children.
2.6. Dextranomer Hyaluronic Acid (Deﬂux). Deﬂux is the
most widely used material for the endoscopic injection of
VUR, we may say that this is the most studied material and
enoughlong-termdataexistinordertounderstandclearlyits
eﬃcacy. The substances composing Deﬂux are dextranomer
(Dx) microspheres and nonanimal Hyaluronic Acid mixed
to form viscous gel consisting of two components. Both
components are made up of polysaccharides sugar-based
molecules. Dextranomer microspheres are formed by cross-
linking dextran polymers into porous beads of 80–250µmi n
diameter.
The overall success rate reported by the diﬀerent groups
of authors with use of Dx/HA copolymer (Deﬂux, Q-Med
Scandinavia, Uppsala, Sweden) ranged between 68–92%
depending mainly on VUR grade [1–3]. Recently, Kirsch
et al. have demonstrated that by utilizing their technique
of Hydrodistention Implantation Technique (HIT) injection
theshort-term resultswiththeendoscopiccorrectionmaybe
closetothose afteropensurgery, and in the caseoflow-grade
reﬂux even similar to those following open reimplantation
[1]. Therefore, the only question of Deﬂux long-term dura-
bility remains the subject of interest and parental concern.
Unfortunately, long-term follow-up data is lacking, as well
as strict criteria for what is considered a “success.” It seems
that the long-term success should be deﬁned on the basis of
the prospective studies, where all patients will be required to
undergotimingVCUGevenafterﬁrstpostoperative-negative
VUR imaging, strict registration of all incidences of febrile
and afebrile UTIs following injection, and the record of all
possible renal parenchymal changes.
Of the available data we brought one meta-analysis that
examined all types of injections, including Dx/HA, which
demonstrated a primary success rate of 78.5% for grades
I and II, 72% for grade III, 63% for grade IV, and 51%
for grade V reﬂux [8]. Many of the studies included in this
meta-analysishadlimitedfollowup,onlysinglepostoperative
VCUG usually within the ﬁrst 3 to 4 months postoperatively.
The early report of 7.5 years of followup after ﬁrst successful
reﬂux correction with Deﬂux from a Swedish group, which
pioneered the use of this tissue augmenting substance,
showed very low reﬂux recurrence [16]. The overall success4 Advances in Urology
Table 2: Long-term results of endoscopic treatment of VUR with Dx/HA.
Author Follow-up time (years) UTI rate after injection (%) Failure rate (%)
L¨ ackgren et al.∗ [16]7 8 1 3
Chertin et al.∗∗ [10]6 2 . 2 3 . 9
Chi et al. [17] 4.8 24 12
Sedberry-Ross et al. [18] 7 27 25
Lee et al. [19]1 N o n e 2 6
Schemedding et al. [20]3 U n k n o w n 2 1
∗The late VCUG was performed in only 45 out of the 334 treated ureters.
∗∗The follow-up VCUG was not performed on a routine basis following postsurgery successfulVCUG.
rate of 84% following ﬁrst VCUG decreased to 74% in
the long-term followup. Reviewing the presented data, only
45 (13.4%) out of the 334 treated ureters examined by
al a t e rV C U Gp e r f o r m e d( Table 2). Moreover, the deﬁned
of the resolution of VUR was considered as “nondilating”
reﬂux. In those patients who had later VCUG, 96% had a
continuedprolongedresolutionalsoatthe2ndand5thyears.
Another study presented by Lee et al. [19]d e m o n s t r a t e d
also a relatively high incidence of VUR recurrence. The
authors retrospectively studied late VUR recurrence veriﬁed
by VCUG, which was performed one year after successful
Deﬂux injection. The initial experience with Dx/HA was
similar to the existing studies, with a postoperative VCUG
success rate of 73%. At one year after endoscopic treatment
39 of 150 ureters exhibited VUR, resulting in a recurrence
rate of 26% and an overall cumulative failure rate of 54%
(130of241ureters).Theoveralllong-termsuccessratehence
was only 46%, and only 74% of the initially successful cases
remained so at within one year. Recently, the working group
of pediatric urology of German Association of Pediatric
Surgeons published results of the multicenter prospective
trial, which aimed to evaluate the long-term eﬃcacy of
endoscopic treatment of VUR utilizing a Dx/HA [20]. A
total of 284 patients (424 RRU) were treated endoscopically
with Deﬂux injection. The reﬂux was corrected in 68% of
all RRU. Forty-six percent of the patients completed 3 years
of followup. In 21% of RRU,a relapse of VUR was diagnosed
between6monthsand3years. Based onthisdatatheauthors
strongly recommended to continue to follow of the patients
even after a successful injection beyond the ﬁrst 3 years after
surgery.
Renal parenchymal damage and UTI incidence following
successful endoscopic correction of VUR. The treatment
of VUR is lacking a based evidence protocol and remains
controversial [7, 27]. Termination of the antibiotic prophy-
laxis in otherwise healthy child with persistent VUR at the
age of 5 years or older is one of the options. Recently,
Kitchens et al. published their results with this approach
[28]. Out of 185 children who have been taken oﬀ antibi-
otic prophylaxis, 29% developed UTI. The majority was
girls (91%) and the majority of UTIs were febrile. All
those patients underwent surgical correction. The authors
concluded that although discontinuation of antibiotics is
a reasonable option, prospective randomized studies are
required in order to decide whether this approach is beneﬁ-
cial.
3.UrinaryTractInfectionfollowingInjection
It has been shown that open surgical correction of VUR
oﬀers a reasonable kidney protection [29–31]. Recent data
published by many researchers clearly demonstrates that
subureteric Teﬂon injection (STING) oﬀers a reasonable
optionforsurgicalcorrectionofVUR.However,thequestion
whether the surgical correction of VUR utilizing an endo-
scopic approach will prevent further renal damage and UTI
d ev e l o p m e n ts t i l ln e e d st ob ea n s w e r e d[ 10,18, 32–34].Since
we have been using the endoscopic approach over the last
two decades in VUR patients, we recently published our data
regarding the changes in the renal function and incidence
of UTI in children who underwent successful endoscopic
correction of VUR utilizing diﬀerent tissue augmenting
substances [10]. We have retrospectively evaluated 507
patients, 169 males and 338 females (696 renal reﬂux units
(RRU)) with a median age of 3.7 years underwent successful
endoscopic correction of primary VUR from 1988 to 2007
with a median, follow-up period of 13 years. Endoscopic
correction was performed utilizing Polytetraﬂouroethylene
(Teﬂon) and Dx/HA copolymer. Reﬂux was Grade 1 in
36 RRU (5.2%), Grade II in 178 (25.6%), Grade III in
298 (42.7%), Grade IV in 163 (23.4%), and Grade V
in 21 (3.1%) renal reﬂuxing units (RRU), respectively.
DMSA scan and renal ultrasound were performed in all
patients preoperatively. Renal ultrasound was performed
in all patients following surgery, and Technetium 99m
dimercaptosuccinic acid (DMSA) scan was performed in
509 (73%) of the 696 RRU postoperatively. DMSA scan
demonstrated renal scarring in 543 (78%) of the 696 RRU
preoperatively. Renal deterioration was demonstrated in 11
of the 26 RRU with initial severe renal scarring (uptake
on DMSA less than 20%). The remaining RRU from this
group demonstrated insigniﬁcant change of 2.3% in the
relative renal function after successful correction of VUR
(P>. 005). Those patients who demonstrated downgrading
of VUR did not show new renal scars. Twenty-seven RRU
(6.1%) of the remaining 446 RRU demonstrated greater
than a 5% decrease in relative renal function without new
scarring. Eleven children (2.2%) (8 in the Teﬂon and 3 in the
Dx/HA copolymer group) developed febrile UTI following
successful endoscopiccorrection, which drove a reevaluation
thatresultedinthediagnosisofVURrecurrencein8(72.7%)
patients. 28 (5.6%) children suﬀered afebrile UTI without
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It has been shown that sterile reﬂux does not cause
renal scars unless extreme hydrodynamic conditions exist
in the sick kidney [17, 18, 34]. VUR-associated bacteriuria,
which leads toaprotracted inﬂammatory reaction, isamajor
cause of exudative pyelonephritis and kidney damage. In
our series, only 2.2% of all the studied children developed
recurrent pyelonephritis in the long-term period. However,
8 of those 11 children showed VUR recurrence on follow-up
VCUG. This data is similar to the previously published one
[17,18].Chietal.andSedberry-Rossetal.haveevaluatedthe
incidence of the febrile UTI following successful endoscopic
correction of VUR. The Dallas group clearly demonstrated
that in 159 patients, of whom 95% had preoperative urinary
tract infections, and all had demonstrated a complete
resolutionof reﬂux after Dx/HAinjection, 40 patients (25%)
hadrecurrentUTI,ofwhichhalfwerefebrile[17].Reimaging
was done in 15 patients with recurrent febrile infections, and
7 had recurrent reﬂux. Another study by the Washington
group of 45 patients, who had undergone successful Dx/HA
injection, demonstrated that12 (27%)had recurrent urinary
tract infections. On reimaging with VCUG, 10 of these
patients (83%) had recurrence of VUR [18].
This data showed that those patients, who had shown
initially VUR correction, but developed febrile UTI in the
long-term followup, require prompt reevaluation in order to
rule out VUR recurrence. Furthermore, in the light of recent
reports regarding the low eﬀectiveness of antibiotic prophy-
laxis in children with VUR, the question is raised whether
we have an optimal tissue augmenting substance which has a
durable long-term eﬃcacy and a good safety proﬁle [35–37].
4.New MaterialforEndoscopicVUR Treatment
4.1. Polyacrylate Polyalcohol Copolymer (Vantris). Biode-
gradable elements of synthetic origin have a high rate
of reabsorption after a year. Non-biodegradable agents of
synthetic origin lead to the formation of a ﬁbrotic cap-
sule, giving stability and long-term permanence. Vantris
(Promedon, Cordoba, Argentina) is categorized into this
last group; it belongs to the family of Acrylics, particles of
polyacrylate polyalcohol copolymer immersed in a glycerol
and physiological solution carrier. Its molecular mass is very
high. When injected in soft tissues, this material causes a
bulkiness that remains stable through time [38].
The carrier is a 40% glycerol solution with a pH of 6.
Once injected, the carrier is eliminated by the reticular
system through the kidneys, without being metabolized.
Particles of this polyacrylate polyalcohol with glycerol are
highlydeformableby compressionand maybeinjected using
a 23-gauge needle. The average of particles size is 320mm.
Once implanted, particles are covered by a ﬁbrotic capsule of
up to 70 microns. Particles of this new material are anionic
with high superﬁcial electronegativity, thus promoting a
low cellular interaction and low ﬁbrotic growth. The new
polyacrylate polyalcohol copolymer with glycerol was tested
for biocompatibility according to ISO 10993-1:2003 in vitro,
showing that they are not mutagenic for the Salmonella T.
strains analyzed. The extract turned out to be noncytotoxic
for cell lines in culture and nongenotoxic for mice. in vivo
studies, acrylate did not cause sensitization in mice. The
macroscopic reaction of tissue irritation was not signiﬁcant
in subcutaneous implants and in urethras of rabbits. Seven
female dogs were injected transurethrally with Vantris to
evaluate short- and long-term migration (13 weeks and
12 months, resp.). No particles or signs of inﬂammation
or necrosis are observed in any of the organs examined
13 weeks and 12 months after implantation. It seems that
Vantris is meeting the criteria of the ideal tissue augmenting
substance. The clinical experience with Vantris is still very
limited. Eighty three patients were treated between 2005 and
2006 during multicenter trial in South America [39]. Sixty-
one patients with an average age of 58 months completed
a one-year followup. The number of injected ureters was
88 (27 (44%) of the patients had bilateral and 34 (55.7%)
unilateral VUR). Thirty-two had grade II (36.4%), 41 grade
III (46.6%), 12 grade IV (13.6%), and 3 units had grade V
(3.4%), respectively. The injected volume per unit ranged
from 0.2 to 1.6mL, with a mean of 0.76mL. The average
follow-up period was 20 months with a range of 16 to 24
months. Reﬂux was eliminated in 78 (88.6%) kidney renal
units; reﬂux decreased to grade I in 6 (6.8%) units and it
persisted in 4 (4.6%) units, respectively. The overall success
rate was of 83.6%. We have recently started in our institution
a prospective trial aiming to see the short- and long-term
eﬃcacy of Vantris in children with VUR. Over the last 16
months, 59 children (22 males and 37 females), with a mean
age of 9.6 years (range 1.2–18 years), underwent endoscopic
treatment of VUR utilizing Vantris. VUR was unilateral in
29 (49.2%) and bilateral in 30 (50.8%) patients, comprising
59 renal reﬂuxing units (RRU). Of those, primary VUR was
in 53 (71.6%) RRU and 21 (28.4%) comprised complex
cases: 5 (6.75%) duplex systems, 1 (1.4%) with Prune Belly
syndrome, and 15 (20.3%) after failed previous endoscopic
correction with Deﬂux. VUR was Grade I in 9 (12.1%),
Grade II in 14 (18.9%), Grade III in 29 (39.2%), Grade IV
in 17 (23%), and Grade V in 5 (6.8%) RRU, respectively.
The reﬂux was corrected in 63 (85%) of 74 RRU, who
completed 3-month followup and underwent VCUG after
a ﬁrst injection and after a second injection in 3 additional
ureters. In 5 (6.8%) RRU reﬂux downgraded to grade 1;
they have been taken oﬀ antibiotics and did not require any
treatment. Three (4%) RRU failed ﬁrst injection and are
awaiting a second trial of the endoscopic treatment. Twenty
one (55.3%) of the 38 patients completed a year of followup.
Their USdemonstrated no changescompared totheimaging
performed one month after injection. In 8 (38.1%) of the 21
children who underwent one year radionuclide cystography,
no reﬂux recurrence was shown. This short-term data shows
that Vantris injection provides a high reﬂux resolution.
However, more clinical data with longer followup is waiting
with this tissue augmenting substance.
5.Conclusions
Many materials has been used for the endoscopic correction
of VUR; although PTFE gave long-term high success rate6 Advances in Urology
its use was abandoned due to the fear of particle migration.
All other substances did not show high success rate and are
no longer in use. The currently worldwide used material
for endoscopic treatment is Dx/HA. Despite short-term
reported high success rate, there is a signiﬁcant shortage
of evidence-based literature on the long-term followup
after endoscopic correction of reﬂux utilizing Dx/HA, the
FDA approved tissue augmenting substance for endoscopic
correction ofVUR.However, thescanty dataavailable clearly
demonstratedthatthereare ahighrecurrence rateduringthe
long-term followup after Dx/HA injection, which requires
close observation beyond the routine protocols and correct
parental counseling upon the endoscopic correction.
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